Skip to main content
Caplight Logo









SignPath Pharma, Inc.

SignPath Pharma, Inc.

Private
Sandy, UtahHealthcare & Life Scienceshttps://signpathpharma.com/

Last Round

VC Round

Jul 25, 2025

Total Funding Raised

$847,500

Momentum

Top 50%

of companies Caplight tracks

Company Overview

SignPath Pharma, Inc. is a clinical-stage biotechnology company that develops proprietary liposomal formulations of curcumin and other therapeutics to treat cancer and mitigate cardiac side effects.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug deliveryliposomal formulationoncology therapeuticsclinical trialscardioprotectiondrug developmentbioavailabilitybiotech startupdrug licensingglioma treatmentpharma R&Ddrug delivery platformclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SignPath Pharma, Inc. Comparables

Compare SignPath Pharma, Inc. with similar companies based on industry and business-model similarity.

SignPath Pharma, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Bexion Pharmaceuticals
78%
ForDoz Pharma Corp.
77%
Moleculin Biotech, Inc.
73%

SignPath Pharma, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJul 25, 2025
Private PlacementJul 26, 2011
DebtApr 1, 2008

Key People

Founding team and executive leadership

Kai Larson

President and CEO

Executive Team

Pete Childs

Senior Vice President, Chief Financial Officer

Executive Team

SignPath Pharma, Inc. Investors

Notable investors and investment history

SignPath Pharma, Inc. investors
InvestorRounds
The Michael J. Fox Foundation for Parkinson's ResearchGrant
Wickfield CapitalVC Round
Loop Capital Markets LLCVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 13, 2026

    Monthly visitors increased 38% MoM, reaching 2.2K.

  • Apr 17, 2026

    Monthly visitors grew 177% MoM, reaching 1.6K.

SignPath Pharma, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SignPath Pharma, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SignPath Pharma, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSandy, Utah
Employee Range11
Year Founded2006
Last FundingJul 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?